Trends in Pharmacological Sciences

Learning about kainate receptors
pp. 159-160(2)
Authors: Reid C.A.; Bliss T.V.P.

-Secretase revealed: starting gate for race to novel therapies for Alzheimer's disease
pp. 161-163(3)
Authors: Skovronsky D.M.; Lee V.M.-Y.

Nitric oxide, glial cells and neuronal degeneration in parkinsonism
pp. 163-165(3)
Authors: Hirsch E.C.; Hunot S.

Reply: a new look at the pathogenesis of Parkinson's disease
pp. 165-165(1)
Authors: Przedborski S.; Vila M.; Jackson-Lewis V.; Dawson T.M.

Tachykinin autoreceptors in the gut
pp. 166-166(1)
Authors: Patacchini R.; Maggi C.A.; Holzer P.

Identification of the real molecular target for HIV inhibitors
pp. 167-168(2)
Author: De Clercq E.

The many faces of binding artefacts
pp. 168-169(2)
Author: Rovati G.E.

Reply: effect of radioligand contamination on the analysis of homologous competition experiments
pp. 169-169(1)
Authors: Lazareno S.; Birdsall N.J.M.

Inflammation-coagulation network: are serine protease receptors the knot?
pp. 170-172(3)
Authors: Cirino G.; Napoli C.; Bucci M.; Cicala C.

The troubled story of tachykinins and neurokinins
pp. 173-175(3)
Author: Maggi C.A.

Using green fluorescent proteins to study G-protein-coupled receptor localization and trafficking
pp. 175-180(6)
Authors: Kallal L.; Benovic J.L.

Identification of PKC-isoform-specific biological actions using pharmacological approaches
pp. 181-187(7)
Authors: Way K.J.; Chou E.; King G.L.

Is agmatine a novel neurotransmitter in brain?
pp. 187-193(7)
Authors: Reis D.J.; Regunathan S.

Anti-leukotrienes: the promise for asthma? - Novel Inhibitors of Leukotrienes [Series: Progress in Inflammation Research (edited by Michael J. Parnham)] edited by G. Folco, B. Samuelsson and R.C. Murphy
pp. 194-194(1)
Author: Barnes P.J.